Cargando…

Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease

Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis. Fortunately, successful eradication of the virus has been associated with improved clinical outcome and reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Maan, Raoel, van der Meer, Adriaan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798156/
https://www.ncbi.nlm.nih.gov/pubmed/27006761
http://dx.doi.org/10.12688/f1000research.7399.1
_version_ 1782422096270327808
author Maan, Raoel
van der Meer, Adriaan J.
author_facet Maan, Raoel
van der Meer, Adriaan J.
author_sort Maan, Raoel
collection PubMed
description Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis. Fortunately, successful eradication of the virus has been associated with improved clinical outcome and reduced mortality rates. In the past few years, treatment has improved considerably by the implementation of direct-acting antivirals (DAAs). From 2014 onwards, sofosbuvir, simeprevir, daclatasvir, ledipasvir, paritaprevir, ombitasvir, and dasabuvir have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Regimens with various combinations of these new drugs, without the use of interferon (IFN), proved to be very effective and well tolerated, even among patients with advanced liver disease. Moreover, treatment duration could be shortened to 12 weeks in the majority of patients. The high costs of these DAAs, however, limit the availability of IFN-free therapy worldwide. Even in wealthy countries, it is deemed necessary to prioritize DAA treatment in order to limit the immediate impact on the health budget. As patients with advanced liver disease are in most need of HCV clearance, many countries decided to treat those patients first. In the current review, we focus on the currently available IFN-free treatment options for patients with cirrhosis. We discuss the virological efficacy as well as the clinical relevance of these regimens among this specific patient population.
format Online
Article
Text
id pubmed-4798156
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-47981562016-03-21 Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease Maan, Raoel van der Meer, Adriaan J. F1000Res Review Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis. Fortunately, successful eradication of the virus has been associated with improved clinical outcome and reduced mortality rates. In the past few years, treatment has improved considerably by the implementation of direct-acting antivirals (DAAs). From 2014 onwards, sofosbuvir, simeprevir, daclatasvir, ledipasvir, paritaprevir, ombitasvir, and dasabuvir have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Regimens with various combinations of these new drugs, without the use of interferon (IFN), proved to be very effective and well tolerated, even among patients with advanced liver disease. Moreover, treatment duration could be shortened to 12 weeks in the majority of patients. The high costs of these DAAs, however, limit the availability of IFN-free therapy worldwide. Even in wealthy countries, it is deemed necessary to prioritize DAA treatment in order to limit the immediate impact on the health budget. As patients with advanced liver disease are in most need of HCV clearance, many countries decided to treat those patients first. In the current review, we focus on the currently available IFN-free treatment options for patients with cirrhosis. We discuss the virological efficacy as well as the clinical relevance of these regimens among this specific patient population. F1000Research 2016-03-17 /pmc/articles/PMC4798156/ /pubmed/27006761 http://dx.doi.org/10.12688/f1000research.7399.1 Text en Copyright: © 2016 Maan R and van der Meer AJ http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Maan, Raoel
van der Meer, Adriaan J.
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease
title Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease
title_full Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease
title_fullStr Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease
title_full_unstemmed Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease
title_short Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease
title_sort recent advances in managing chronic hcv infection: focus on therapy in patients with severe liver disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798156/
https://www.ncbi.nlm.nih.gov/pubmed/27006761
http://dx.doi.org/10.12688/f1000research.7399.1
work_keys_str_mv AT maanraoel recentadvancesinmanagingchronichcvinfectionfocusontherapyinpatientswithsevereliverdisease
AT vandermeeradriaanj recentadvancesinmanagingchronichcvinfectionfocusontherapyinpatientswithsevereliverdisease